Greenwood Capital Associates LLC Has $5.43 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Greenwood Capital Associates LLC decreased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 44.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,398 shares of the company’s stock after selling 142,082 shares during the period. Greenwood Capital Associates LLC’s holdings in Teva Pharmaceutical Industries were worth $5,434,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in TEVA. Quantum Portfolio Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $437,000. Swedbank AB bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth $11,454,000. Sage Rhino Capital LLC increased its holdings in Teva Pharmaceutical Industries by 5.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,874 shares of the company’s stock worth $237,000 after purchasing an additional 417 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in Teva Pharmaceutical Industries by 4.9% in the 1st quarter. V Square Quantitative Management LLC now owns 23,290 shares of the company’s stock worth $701,000 after purchasing an additional 1,080 shares in the last quarter. Finally, QRG Capital Management Inc. raised its position in Teva Pharmaceutical Industries by 4.9% in the first quarter. QRG Capital Management Inc. now owns 76,153 shares of the company’s stock valued at $2,294,000 after purchasing an additional 3,580 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TEVA. Truist Financial lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Finally, Piper Sandler reissued an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $41.78.

Insider Buying and Selling

In other news, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider owned 80,760 shares in the company, valued at $2,825,792.40. The trade was a 64.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the transaction, the executive vice president owned 172,184 shares of the company’s stock, valued at $6,131,472.24. This trade represents a 47.09% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $33.25 on Thursday. The company has a fifty day moving average of $34.16 and a 200-day moving average of $32.66. The firm has a market capitalization of $38.23 billion, a P/E ratio of 25.00, a P/E/G ratio of 4.23 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.